Skip to main content

The Choice of Leaders

The Choice of Leaders

As the second-most populous nation on Earth, India is naturally one of the biggest potential markets for hernia repair products. Bard began a direct sales operation there in 2004; a sales force expansion beginning in 2012 nearly quadrupled business in just four years. It was during this time that Dr. Pradeep Chowbey, Chairman of the Max Institute of Minimal Access, Metabolic & Bariatric Surgery in New Delhi, adopted Davol’s hernia repair products as his own standard of care.
 
Dr. Chowbey—who has served as a surgeon to the Dalai Lama and honorary surgeon to the president of India—is a pioneer of laparoscopic ventral hernia repair (LVHR) surgery on the subcontinent, where he has been performing the minimally invasive procedure for more than two decades. For LVHR, he relies on the Ventralight® ST Mesh, which features an uncoated lightweight monofilament polypropylene mesh on the anterior side with an absorbable hydrogel barrier based on Sepra® technology1 on the posterior side.

Because of its low-profile design, “the Ventralight® ST Mesh ensures easy handling and positioning; even larger mesh sizes can be accommodated in the trocars,” Dr. Chowbey explains. “I like the hydrogel barrier, which is different from other meshes.” The hydrogel barrier is designed to minimize the chances of tissue attachment to the mesh.2 “In my opinion and experience, Ventralight® ST Mesh provides a strong repair and better patient outcomes due to the unique hydrogel barrier,” he says.


The mesh itself is just one component of a successful hernia repair procedure. Depending on the nature of the individual case, Dr. Chowbey uses either the SorbaFix™ Absorbable Fixation System or the CapSure™ Permanent Fixation System, which was recently introduced in India and features a smooth polyetheretherketone cap that eliminates the exposed metal tip, which is designed to minimize adhesions to the fastener.* “The CapSure™ fixation system was one product which I was looking forward to using,” he says. “My initial experience is promising.”

With the support of respected surgeons like Dr. Chowbey and an enormous market for hernia repair devices that has barely been tapped, Bard’s potential in India looks promising as well.

 

  1. Preclinical data on file at C. R. Bard. Results may not correlate to performance in humans.
  2. Sepra technology is licensed from Sanofi Genzyme.